Problem

Latent addresses the gap between diagnosis and treatment in specialty medication access, where prior authorization forces physicians and pharmacy teams to search medical records, answer insurer questions, and assemble documentation proving that an expensive drug is medically necessary. Forbes reports that physicians spend an average of 13 hours a week on this work, while duplicated review by providers and payers can delay critical medication. The central use case is accelerating approval of specialty drugs, including preparing an effective response when an insurer denies the initial request.

The pain is both clinical and economic: patients wait longer to start therapy, and highly trained clinicians spend substantial time on repetitive administrative work instead of patient care. The stakes are amplified by the size of the specialty-drug market, which Forbes characterizes as approximately $200 billion, and by the labor cost of manual pharmacy operations.

Product / Service

Latent sells an enterprise pharmacy-intelligence platform to health systems. Its single clinical agentic engine reads the patient chart, claims, payer policies, and drug labels, then supports the pharmacy workflow across patient identification, prior-authorization submission, denial appeals, prescription capture, outreach, and adherence. The platform natively integrates with EHRs, and its outputs trace back to the chart; providers remain involved so a human can approve the final request.

The benefit is to automate administrative heavy lifting while preserving clinical oversight, allowing pharmacists and other clinical staff to focus on patients and practice at the top of their license. Latent reports $50 million in copay assistance accessed, 23.4 minutes of pharmacist time returned per appeal, 109% more prior-authorization throughput per team member on the same staff, and at least $300,000 in annual labor cost avoided plus multi-million-dollar net-new specialty revenue in a customer example.

Market

Latent competes in enterprise healthcare AI, more specifically pharmacy-intelligence and medication-access automation for health systems. Its closest overlaps are prior-authorization automation providers such as Surescripts, whose product matches clinical data to determination criteria at prescribing, and Cohere Health, which offers prior-authorization solutions. Latent is differentiated in the available materials by positioning one clinical engine across the broader pharmacy stack rather than only the initial authorization step.

The company is clearly commercial rather than pre-revenue: Latent says it is trusted by more than 50 leading health systems, including Ochsner, Yale New Haven, Mount Sinai, UCLA, UCSF, and Henry Ford, and reports helping more than 2 million patients annually. It raised $80 million in total funding by March 2026 and has published customer case studies with operational and financial outcomes. The available evidence does not disclose revenue figures, so customer count, patient volume, reported ROI, and funding are the clearest public indicators of traction.